Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight ... New York City-based biotech firm is developing injectable and oral ...

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs ... of the two most popular weight loss drugs, Ozempic and Wegovy.

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.